Details of the Drug Combinations

General Information of This Drug (ID: DM6034S)

• Drug Name: Selegiline (DM6034S)
• Synonyms: selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic

Indication

Major depressive disorder; ICD 11: 6A70.3; Status: Approved [1]; Skin imperfections; ICD 11: EK71; Status: Patented [2]; Chemotherapy-induced nausea; ICD 11: MD90; Status: Discontinued in Phase 3 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Selegiline + Docetaxel	DCX5JW7	Docetaxel	Metastatic Castration-resistant Prostate Cancer	[4]
Selegiline + Tadalafil	DCQG3VC	Tadalafil	Parkinson's Disease	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6639).
• [2] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [3] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [4] ClinicalTrials.gov (NCT04586543) Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
• [5] ClinicalTrials.gov (NCT02225548) Sagene 2014 - Parkinson's Disease and Erectile Dysfunction